Skip to main content

Advertisement

Table 1 Characteristics of included trials

From: Efficacy and safety of Tripterygium wilfordii hook F for chronic urticaria: a systematic review and meta-analysis

Study (author/year) Sample size (I/C) Average courses (\( \overline{\mathrm{X}} \)[SD]) Interventions Course of treatment Used instruments in the study
T C T C
Pi 2006 [13] 21/22 1.30 [2.03] y TG + Mizolastine Mizolastine ≤12 w LFS, SSRI, ADE
Zhang 2007 [14] 86/82 0.85 y TwHF + Levocetirizine Levocetirizine 4 w LFS, SSRI, ADE
Bao 2008 [15] 87/80 1.60 y GTT + Desloratadine Desloratadine 4 w LFS, SSRI, ADE
Xu2009 [16] 54/54 1.08 y 1.17 y TG + Desloratadine Desloratadine 4 w LFS, SSRI, ADE, RER
Wei 2010 [17] 90/90 6.25 y 6.20 y GTT + Desloratadine Desloratadine 4 w LFS, SSRI, ADE, DLQI
Zhong 2011 [18] 40/38 16.75 y 16.25 y THH + Cetirizine Hydrochloride Placebo + Cetirizine Hydrochloride 4 w LFS, TER, ADE
Liu 2011 [19] 98/90 16.20 [0.96] y GTT + Levocetirizine Hydrochloride Levocetirizine Hydrochloride 4 w LFS, SSRI, ADE
Qian 2011 [9] 180/180 6.72 [3.47] y 6.51 [3.76] y TG + Loratadine; TG + Mizolastine; TG + Cetirizine Loratadine; Mizolastine; Cetirizine 4 w LFS, UAS,S SRI, ADE, DLQI, RER
Yu 2011 [20] 48/47 1.7 y THH + Terfenadine Terfenadine 4 w SA, ADE
Lu 2012 [21] 40/40 3.20 [1.60] y 3.20 [1.20] y TG + Fexofenadine hydrochloride Fexofenadine hydrochloride 4 w LFS, SSRI, ADE
Zhou 2012 [22] 60/60 3.97 [2.97] y 3.45 [2.72] y THH + Mizolastine + Ketotifena Mizolastine + Ketotifena 8 w UAS, SSRI, ADE
Fan 2013 [23] 43/41 2.70 y 2.77 y GTT + Ebastine Ebastine 4 w LFS, SSRI
Liu 2013 [24] 89/90 ≥0.13 y TG + Cetirizine Hydrochloride Cetirizine Hydrochloride 4 w LFS, VAS, SSRI, ADE, RER
Zheng 2013 [25] 37/37 ≥0.13 y GTT + Desloratadine Desloratadine 4 w LFS ,SSRI, ADE,DLQI, RER
Chen 2014 [26] 45/46 3.70 [1.30] y 3.90 [1.10] y GTT + Fexofenadine Fexofenadine 4 w UAS, VAS, LFS, ADE
Wang 2014 [27] 32/32 ≥0.13 y GTT + Desloratadine Desloratadine 4 w SA, ADE
Zhou 2014 [28] 60/60 ≥0.13 y GTT + Desloratadine Desloratadine 4 w LFS, SSRI, ADE, RER
Li 2016 [29] 36/34 ≥0.13 y TG + Ebastine Ebastine 4 w SA, ADE
Liu 2016 [30] 60/60 0.53 [0.27] y 0.58 [0.33] y GTT + Desloratadine Desloratadine 4 w LFS, SSRI, ADE, DLQI
Chen 2017 [31] 45/45 0.56 [0.32] y 0.53 [0.27] y GTT + Desloratadine Desloratadine 4 w SA, ADE
Tao 2017 [32] 48/49 2.46 [0.52] y 2.53 [0.63] y GTT + Desloratadine Desloratadine 4 w LFS, SSRI, ADE, DLQI, RER
  1. aAdministered ketotifen for 4 weeks
  2. TwHF Tripterygium wilfordii Hook F, GTT Glucosidorum Tripterygll Totorum, TG Tripterygium Glycosides, THH Tripterygium hypoglaucum (levl.) Hutch, LFS Four-level Score Method, UAS Urticaria Activity Score, SSRI Symptom Score Reduce lndex, ADE Adverse Events, DLQI Dermatology Life Quality Index, RER Recurrence Rate, TER Total Effective Rate, VAS Visual Analogue Scales, SA Symptom Assessment